Like all living organisms, malaria parasites need iron for vital cell
functions and must handle their cellular contents in a highly regulate
d fashion. However, in the asexual stage of growth, parasites present
a special case of iron metabolism. Despite dwelling in a sea of hemogl
obin and carrying inside the remnants of its degradation products, int
racellular parasites have no obvious means for mobilizing bioavailable
iron from the host or from the medium. In that sense they differ from
most mammalian cells which are exposed to body fluids and acquire the
metal from circulating iron carriers. The uniqueness of iron handling
by parasites is manifested in their susceptibility to drug-induced de
privation of the metal. Both natural and synthetic iron(III) chelators
of the hydroxamate family have been shown to abolish cell growth in v
itro, and to reduce malaria infection in vivo as well os in the clinic
. Z. loav Cabantchik here explores the molecular basis for the selecti
ve cytotoxicity of iron(III) hydroxamate chelators and the potential o
f iron chelation therapy in the management of malaria.